Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6376659 | 1.00 | BCHE (0.67) | BCHEKDM4EMAPTGAAHTT | |
| SCHEMBL6375550 | 1.00 | BCHE (0.67) | BCHEKDM4EMAPTGAAHTT | |
| SCHEMBL9416585 | 1.00 | BCHE (0.67) | BCHEKDM4EMAPTGAAHTT | |
| SCHEMBL18736057 | 0.98 | KDM4E (0.68) | BCHEKDM4EMAPTGAAHTT | |
| SCHEMBL18736029 | 0.98 | KDM4E (0.68) | BCHEKDM4EMAPTGAAHTT | |
| SCHEMBL5209588 | 0.94 | BCHE (0.58) | BCHEKDM4EMAPTGAAHTT | |
| SCHEMBL10548574 | 0.91 | ADRB2 (0.64) | BCHEKDM4EMAPTGAAHTT | |
| SCHEMBL6391844 | 0.91 | BCHE (0.61) | BCHEKDM4EMAPTGAAHTT | |
| SCHEMBL17212225 | 0.89 | BCHE (0.58) | BCHEKDM4EMAPTGAAHTT | |
| SCHEMBL17212223 | 0.89 | BCHE (0.58) | BCHEKDM4EMAPTGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274687-B1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-01-05 | — | — | EP | disclosed |
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-1274687-A1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001068609-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | BCHE 2321/4885KDM4E 1711/4885MAPT 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.